Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees, and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD, PrecisionCHD, and the HeartRisk population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains a significant burden on the healthcare system and employers. By presenting at these conferences, Cardio Diagnostics aims to highlight how its precision medicine solutions can enable earlier detection and personalized management of cardiovascular risk. The company’s AI-driven Integrated Genetic-Epigenetic Engine leverages proprietary technology to provide insights that go beyond traditional risk factors.
The Epi+Gen CHD test is a blood-based epigenetic and genetic test that assesses coronary heart disease risk. PrecisionCHD is a comprehensive test that integrates genetic, epigenetic, and clinical factors to provide a personalized risk score. The HeartRisk platform offers population-level insights, allowing employers and plan administrators to identify high-risk groups and implement targeted interventions.
The implications of this announcement are significant for employers and health plans. Cardiovascular disease is a leading cause of healthcare spending and lost productivity. By adopting these AI-powered tools, benefits decision-makers can potentially reduce costs through early intervention and more precise risk stratification. This could lead to better health outcomes for employees and lower premiums for plan sponsors.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease.
For more information about Cardio Diagnostics, visit the company’s newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/qFRHu.
